ExeVir Announces Michael Garrett as New Chief Executive Officer
Company developing antibody therapeutics against emerging viral threatsMichel
Poster ID Week 2024
Poster presented by Florence Herschke at ID Week 2024, October 16-19, 2024, Los Angeles, USA
Empowering the Immunocompromised and Elderly: ExeVir Bio presents promising XVR013m data at ID Week 2024
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
Photo by Önder Örtel on Unsplash
Join us at the Asia Dengue Summit 2024!
Connect with Florence Herschke, PhD, our head of preclinical development, and Tessa Van Royen, one of our research scientists, next week at the 7th Asia Dengue Summit in Kuala Lumpur.
Poster ESCMID Global 2024 Conference
Poster presented by CSO Viki Bockstal at ESCMID Global, 27–30 April 2024 in Barcelona, Spain
Member spotlight: ExeVir uses llama-derived antibodies to protect the vulnerable
MEDVIA article featuring ExeVir – Based on the interview with CSO, Viki Bockstal.
By Amy LeBlanc.
Images: Winter the llama ©Tim Coppens
Exevir at ECCMID 2024
Our Chief Scientific Officer Viki Bockstal is presenting a poster at ECSMID Global 2024 (formerly known as ECCMID) from 27-30 April in vibrant Barcelona, the Mediterranean’s #lifesciences hub!
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Bio-Europe – November 6-8, 2023 – Munich, Germany
Our CEO Torsten Mummenbrauer is attending #BIOEurope in Munich, November 6-8!